PDCD1 and neoplasm: Consistently, genetic inhibition of Cda significantly improved the survival rate of KPC FC1245 tumor-bearing mice after anti-PD-1 treatment, whereas the three other conditions were unchanged (Fig. 2f), supporting the idea that CDA targeting overcomes anti-PD-1 resistance.